

Performance Against First Patient Visit Benchmark

Ethics Committee Ref	Project Title	Project Site R&D Submission	Date of First Patient Consented	Benchmark Met or Reason for Delay
12/SS/0138	RESTART study	26/03/2014	20/05/2014	Benchmark met
12/SC/0014	Vasopressin vs Noradrenaline as Initial therapy in Septic Shock (Vanish)	03/04/2014	05/06/2014	Benchmark met
13/NE/0049	MCRN224 (BAY 94-9027)	28/03/2014	03/06/2014	Benchmark met
13/YH/0152	FIGARO	21/03/2014	28/07/2014	Reasons for delay rest with the Sponsor
14/SW/0028	ACORN - Improving diagnosis with endocervical curettage and P16 staining	07/04/2014	06/05/2014	Benchmark met
13/SC/0111	FOCUS 4	09/04/2014	23/05/2014	Benchmark met
13/NI/0143	SIEGE	02/04/2014	23/05/2014	Benchmark met
14/SC/0100	JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated With JETREA® for Vitreomacular Traction	15/04/2014	03/06/2014	Benchmark met
12/LO/0145	DRN 840 (CLEOPATRA)	29/04/2014	04/07/2014	Benchmark met
GTAC182	TRIOC	30/04/2014	06/10/2014	Reasons for delay rest with the Sponsor
14/SW/0079	CCRN - 3308 The DEFLECT III Trial	11/05/2014	13/05/2014	Benchmark met
13/NW/0705	COAST BAY73-4506/15983: Regorafenib as adjuvant therapy for resected liver metastases	12/05/2014	21/08/2014	Delays due to external factors outside the control of the Sponsor and Trust
14/LO/0036	NCRN2555 - TOWER Study (00103311)	29/04/2014	03/03/2015	Reasons for delay rest with the Trust
12/EE/0445	PREVENTT (Preoperative intravenous iron to treat anaemia in major surgery)	12/05/2014		Delays due to external factors outside the control of the Sponsor and Trust
13/NW/0609	Alight (AMD light trial)	12/05/2014	09/07/2014	Benchmark met
13/YH/0201	MCRN2280 Sativex Severe Spasticity (GWSP08258)	06/05/2014	23/09/2014	Reasons for delay rest with the Sponsor
11/YH/0290	STOMP	01/05/2014	14/08/2014	Reasons for delay rest with the Sponsor
12/WA/0230	ROCS: Radiotherapy after Oesophageal Cancer Stenting Study	09/06/2014	17/07/2014	Benchmark met
13/YH/0126	GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma	06/06/2014	16/07/2014	Benchmark met
12/NW/0827	Euro Ewing 2012	09/06/2014	08/09/2014	Reasons for delay rest with the Sponsor
13/NE/0197	RDP Trial (Ranibizumab for DMO PRP trial)	09/06/2014	05/09/2014	Reasons for delay rest with the Trust
10/H0203/70	Fluid Management in 10-15% BSA scalds	12/06/2014	22/10/2014	Delays due to external factors outside the control of the Sponsor and Trust
14/YH/0007	MCRN2368 UCB PRA Epilepsy Lacosamide SP0969	12/06/2014		Delays due to external factors outside the control of the Sponsor and Trust
14/WS/0004	Odyssey OLE	30/05/2014	31/07/2014	Benchmark met
13/SC/0557	THAPCA-IH-UK	17/06/2014		Delays due to external factors outside the control of the Sponsor and Trust
13/NE/0225	Pharmacokinetic variation and toxicity in Ewing's sarcoma (PK 2013 01)	20/06/2014	10/09/2014	Delays due to external factors outside the control of the Sponsor and Trust
14/YH/0048	Apposition V	23/06/2014	09/07/2014	Benchmark met
13/EE/0397	NIMRAD (NIMorazole/placebo plus RAdiotherapy in head and neck cancer)	01/07/2014	18/12/2014	Delays due to external factors outside the control of the Sponsor and Trust
14/NE/0122	WA29231- LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS	11/06/2014	16/07/2014	Benchmark met
13/LO/0716	CCRN 2159 (Uveitis)	25/06/2014		Delays due to external factors outside the control of the Sponsor and Trust
13/LO/0717	CL3-78989-006. EYEGUARD-C study	25/06/2014	07/01/2015	Delays due to external factors outside the control of the Sponsor and Trust
13/LO/1608	Study of efficacy and safety of nilotinib in paediatric CML patients	07/07/2014	16/12/2014	Delays due to external factors outside the control of the Sponsor and Trust
14/EM/0034	NCRN3025 - GDC-0199 in CLL (GO28667) - MURANO	16/07/2014	22/10/2014	Delays due to external factors outside the control of the Sponsor and Trust
13/LO/1329	3H (Hemodiafiltration, Heart and Heights) study	28/07/2014	01/09/2014	Benchmark met
13/LO/1463	InterAACT - A Multicentre Randomised Phase II Advanced Anal Cancer Trial	14/08/2014		Delays due to external factors outside the control of the Sponsor and Trust
14/EE/0105	EORTC protocol 26101	19/08/2014	15/09/2014	Benchmark met
13/NW/0702	ABC-06: ASC alone or with mFOLFOX for advanced biliary tract cancer	20/08/2014	08/10/2014	Benchmark met
14/NW/0008	GO-COLITIS	26/08/2014	21/11/2014	Reasons for delay rest with the Sponsor
13/LO/1515	Predicting Language Outcome & Recovery after Stroke	26/08/2014	01/09/2014	Benchmark met
14/LO/0203	CLARITY	28/08/2014	17/10/2014	Benchmark met
13/EM/0395	Treatment of Advanced Glaucoma Study (TAGS)	04/09/2014	05/12/2014	Delays due to external factors outside the control of the Sponsor and Trust
14/SW/0114	The effect of Plasma Rich in Growth Factors (PRGF) on periodontal tissue regeneration	28/08/2014	01/10/2014	Benchmark met
14/EM/0130	NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy	15/09/2014	08/01/2015	Delays due to external factors outside the control of the Sponsor and Trust
13/EE/0367	CCRN 2215 (Crohn's)	05/09/2014	17/12/2014	Delays due to external factors outside the control of the Sponsor and Trust


Performance Against First Patient Visit Benchmark

Ethics Committee Ref	Project Title	Project Site R&D Submission	Date of First Patient Consented	Benchmark Met or Reason for Delay
13/EM/0149	15961 GadaCAD1	18/09/2014		Reasons for delay rest with the Trust
14/WM/0159	The SNIFFLE 2 Study	29/09/2014	09/10/2014	Benchmark met
12/NW/0790	The BASICS Trial	03/10/2014	09/10/2014	Benchmark met
14/NW/1256	RVENCH	29/09/2014	26/10/2014	Benchmark met
11/H1307/6	SWITCH	14/10/2014	10/11/2014	Benchmark met
13/SC/0619	Group B streptococcus Immunisation Attitudes	01/10/2014	23/10/2014	Benchmark met
13/EM/0154	SWIFFT Trial	04/09/2014	12/11/2014	Benchmark met
14/NS/0089	Hip 'OP	17/10/2014		Delays due to external factors outside the control of the Sponsor and Trust
14/SC/0221	CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of Her2 negative metastatic breast cancer (mBC)	21/10/2014	18/12/2014	Benchmark met
14/EE/1063	AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy (AURA3)	29/10/2014	13/01/2015	Delays due to external factors outside the control of the Sponsor and Trust
13/SC/0007	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Unresectable Melanoma.	03/11/2014	28/11/2014	Benchmark met
12/WM/0187	ROCSS	13/11/2014	09/12/2014	Benchmark met
14/EE/1001	OTO-104 in Meniere's Disease	13/11/2014	17/12/2014	Benchmark met
14/SW/1101	The effect of Plasma Rich in Growth Factors (PRGF) on the treatment of dry sockets	03/11/2014	24/11/2014	Benchmark met
14/WM/0085	Robot Assisted Fracture Surgery (RAFS)	12/11/2014	19/12/2014	Benchmark met
14/SC/1014	CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in pancreatic adenocarcinoma	20/11/2014	21/01/2015	Benchmark met
14/LO/1428	Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study	01/12/2014		Delays due to external factors outside the control of the Sponsor and Trust
14/SC/1269	CAIRO WPC: PROXY: Post ROSC OXYgenation Study	18/12/2014	17/01/2015	Benchmark met
07/H0718/57	UKAITPR	18/12/2014	08/01/2015	Benchmark met
13/SC/0268	CCRN2100 (Cystic fibrosis)	09/12/2014		Reasons for delay rest with the Sponsor
14/SW/1078	DRIFT School age follow-up (CRN: Children)	14/01/2015	07/02/2015	Benchmark met
13/SC/0171	Study of Moxetumomab Pasudotox in pALL or LL of B-Cell	22/01/2015		70 days not yet reached
14/LO/1043	LEAVO	23/01/2015	16/02/2015	Benchmark met
14/YH/0085	FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab	16/01/2015	06/03/2015	Benchmark met
14/EM/1319	The benefit of ultrasound imaging prior to heart bypass surgery to prevent leg wound complications.	30/01/2015	23/02/2015	Benchmark met
13/WA/0205	AML18	10/02/2015	06/03/2015	Benchmark met
14/SC/1425	CCRN 2738 (AMD)	12/02/2015	25/02/2015	Benchmark met
14/LO/1617	DRN3544 - GLP110933 study Type I DM Study	06/02/2015		70 days not yet reached
14/NI/1075	CHIL3670 (ALX0171-C104)	16/02/2015		70 days not yet reached
14/NE/1099	GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFlixIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS	27/02/2015		70 days not yet reached
14/EM/0215	M12-914 Phase III Veliparib/Placebo + C/P Breast Cancer Study	02/03/2015		70 days not yet reached
14/YH/1124	EXTEND (2819MA1002)	04/03/2015		70 days not yet reached
14/WM/1228	CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric Study (BEAGLE)	05/03/2015	00/01/1900	70 days not yet reached
15/NW/0009	MCRN3127 (20130173)	17/03/2015	00/01/1900	70 days not yet reached

No of days to First Patient Consented

Projects have been colour coded to identify length of time from submission of an application to first patient consented

Key: BLACK - No recruitment > 70 days , RED+ - Recruited > 100 days, RED - Recruited 71 - 100 days, GREEN - Recruited <70 days



Reasons for Delays in First Patient Consented

Internal delay: delay due to UH Bristol Trust issue

Both internal and external delay: contributing factors for delay from both UH Bristol and external party, e.g. contract review

External delay sponsor: examples include delayed site initiation visits, green light visit.

External delay protocol design: protocol stipulates that very rare patient group/low recruitment or other protocol design which means site is unable to reasonably expect to recruit within 70 days.

External delay University: any University involvement contributing to the delay - e.g. contract review

External delay other Trust: a delay caused by an external Trust e.g. reviewing contracts, delaying initiation.

External delay other: any other delays which fall outside the above categories and are due to factors external to the Trust.

